Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 20, Issue 4, 2018, Pages 800-811

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

diabetic nephropathy; renal sodium transport; sodium hydrogen exchanger; tubuloglomerular feedback

Indexed keywords

AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ENKEPHALINASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; INSULIN SENSITIZING AGENT; ISOPROTEIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; SODIUM PROTON EXCHANGE PROTEIN 3; SPIRONOLACTONE; SODIUM;

ALBUMINURIA; DRUG EFFECT; DRUG MECHANISM; ESTIMATED GLOMERULAR FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SODIUM EXCRETION; SODIUM RETENTION; COMPLICATION; GLOMERULUS FILTRATION RATE; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; SODIUM; SODIUM-HYDROGEN EXCHANGERS;

EID: 85043503637     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13191     Document Type: Review

References (246)

1. Górriz JL, Nieto J, Navarro-González JF, Molina P, Martínez-Castelao A, Pallardó LM. Nephroprotection by hypoglycemic agents: do we have supporting data? J Clin Med. 2015;4:1866-1889.
2. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol. 2006;17:S86-S89.
3. Miao Y, Smink PA, de Zeeuw D, Lambers Heerspink HJ. Drug-induced chan-ges in risk/biomarkers and their relationship with renal and cardiovas-cular long-term outcome in patients with diabetes. Clin Chem. 2011;57:186-195.
4. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
5. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419-430.
6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;36:129-139.
7. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334.
8. HY W, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008. https://doi.org/10.1136/bmj.f6008.
9. Shen X, Zhang Z, Zhang X, et al. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2016;15:179.
10. Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun. 2013;433:359-361.
11. Orlowski J, Grinstein S. Na+/H+ exchangers. Compr Physiol. 2011;1:2083-2100.
12. Vallés PG, Bocanegra V, Gil Lorenzo A, Costantino VV. Physiological functions and regulation of the Na+/H+ exchanger [NHE1] in renal tubule epithelial cells. Kidney Blood Press Res. 2015;40:452-466.
13. Dominguez Rieg JA, de la Mora Chavez S, Rieg T. Novel developments in differentiating the role of renal and intestinal sodium hydrogen exchanger 3. Am J Physiol Regul Integr Comp Physiol. 2016;311:R1186-R1191.
14. Donowitz M, Mohan S, Zhu CX, et al. NHE3 regulatory complexes. J Exp Biol. 2009;212:1638-1646.
15. Sun YM, Su Y, Li J, Tian Y, Wang LF. Role of the Na(+)/H(+) exchanger on the development of diabetes mellitus and its chronic complications. Biochem Biophys Res Commun. 2012;427:229-231.
16. Klisic J, Nief V, Reyes L, Ambuhl PM. Acute and chronic regulation of the renal Na/H+ exchanger NHE3 in rats with STZ-induced diabetes mellitus. Nephron Physiol. 2006;102:27-35.
17. Ganz MB, Hawkins K, Reilly RF. High glucose induces the activity and expression of Na(+)/H(+) exchange in glomerular mesangial cells. Am J Physiol Renal Physiol. 2000;278:F91-F96.
18. Hryciw DH, Lee EM, Pollock CA, Poronnik P. Molecular changes in proximal tubule function in diabetes mellitus. Clin Exp Pharmacol Physiol. 2004;31:372-379.
19. Zerbini G, Roth T, Podestá F, et al. Activity and expression of the Na+/H+ exchanger in human endothelial cells cultured in high glucose. Diabetologia. 1995;38:785-791.
20. Li P, Chen GR, Wang F, et al. Inhibition of Na(+)/H(+) exchanger 1 attenuates renal dysfunction induced by advanced glycation end products in rats. J Diabetes Res. 2016;2016:1802036. https://doi.org/10.1155/2016/1802036.
21. Schelling JR, Abu Jawdeh BG. Regulation of cell survival by Na+/H+ exchanger-1. Am J Physiol Renal Physiol. 2008;295:F625-F632.
22. Li K, Su W, Li M, et al. Acid loading stimulates rat glomerular mesangial cells proliferation through Na(+)-H (+) exchanger isoform 1 (NHE1)-depend-ent pathway. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:563-569.
23. Semplicini A, Ceolotto G, Sartori M, et al. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide. J Nephrol. 2002;15:489-496.
24. Lee EM, Pollock CA, Drumm K, Barden JA, Poronnik P. Effects of pathophysiological concentrations of albumin on NHE3 activity and cell proliferation in primary cultures of human proximal tubule cells. Am J Physiol Renal Physiol. 2003;285:F748-F757.
25. Packer M. Activation and inhibition of sodium-hydrogen exchange is a mechanism that links the pathophysiology and treatment of diabetes with that of heart failure. Circulation. 2017;136:1548-1559.
26. Donowitz M, Li X. Regulatory binding partners and complexes of NHE3. Physiol Rev. 2007;87:825-872.
27. Manhiani MM, Cormican MT, Brands MW. Chronic sodium-retaining action of insulin in diabetic dogs. Am J Physiol Renal Physiol. 2011;300:F957-F965.
28. Tiwari S, Riazi S, Ecelbarger CA. Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol. 2007;293:F974-F984.
29. Bełtowski J, Rachańczyk J, Włodarczyk M. Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPAR Res. 2013;2013:628628. https://doi.org/10.1155/2013/628628.
30. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097-2104.
31. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.
32. Fuster DG, Bobulescu IA, Zhang J, Wade J, Moe OW. Characterization of the regulation of renal Na+/H+ exchanger NHE3 by insulin. Am J Physiol Renal Physiol. 2007;292:F577-F585.
33. Gesek FA, Schoolwerth AC. Insulin increases Na(+)-H+ exchange activity in proximal tubules from normotensive and hypertensive rats. Am J Physiol. 1991;260:F695-F703.
34. Saad S, Agapiou DJ, Chen XM, Stevens V, Pollock CA. The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells. Nephrol Dial Transplant. 2009;24:1130-1141.
35. Endo Y, Suzuki M, Yamada H, et al. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling. Cell Metab. 2011;13:550-561.
36. De Cosmo S, Prudente S, Lamacchia O, et al. PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrol Dial Transplant. 2011;26:4011-4016.
37. Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 2005;68:285-292.
38. Dorella M, Giusto M, Da Tos V, et al. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. J Clin Endocrinol Metab. 1996;81:1568-1574.
39. Konstas AA, Bielfeld-Ackermann A, Korbmacher C. Sulfonylurea receptors inhibit the epithelial sodium channel (ENaC) by reducing surface expression. Pflugers Arch. 2001;442:752-761.
40. Chrabi A, Horisberger JD. Stimulation of epithelial sodium channel activity by the sulfonylurea glibenclamide. J Pharmacol Exp Ther. 1999;290:341-347.
41. Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care. 2009;32:2068-2074.
42. Lachin JM, Viberti G, Zinman B, et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol. 2011;6:1032-1040.
43. Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol. 2014;10:88-103.
44. Waldrop G, Zhong J, Peters M, Rajagopalan S. Incretin-based therapy for diabetes: what a cardiologist needs to know. J Am Coll Cardiol. 2016;67:1488-1496.
45. Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:200-207.
46. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015;116:1491-1504.
47. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89:3055-3061.
48. von Scholten BJ, Lajer M, Goetze JP, Persson F, Rossing P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med. 2015;32:343-352.
49. Girardi AC, Fukuda LE, Rossoni LV, Malnic G, Rebouças NA. Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol. 2008;294:F414-F422.
50. Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis. J Hypertens. 2016;34:167-175.
51. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54:965-978.
52. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol. 2007;18:1227-1238.
53. Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res. 2012;36:119-130.
54. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340:248-255.
55. Dicembrini I, Nreu B, Scatena A, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(10):933-941. https://doi.org/10.1007/s00592-017-1031-9.
56. Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40:69-76.
57. Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017;19:1610-1619. https://doi.org/10.1111/dom.13041.
58. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
59. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839-848.
60. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovasc-ular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
61. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-242.
62. US Food and Drug Administration. Diabetes medications containing saxagliptin and alogliptin: drug safety communication – risk of heart failure. April 5, 2016. https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm494252.htm. Accessed September 1, 2017.
63. Verma S, Goldenberg RM, Bhatt DL, et al. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open. 2017;5:E152-E177.
64. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24:689-697.
65. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579-1588.
66. Farah LX, Valentini V, Pessoa TD, Malnic G, McDonough AA, Girardi AC. The physiological role of glucagon-like peptide-1 in the regulation of renal function. Am J Physiol Renal Physiol. 2016;310:F123-F127.
67. Yang LE, Sandberg MB, Can AD, Pihakaski-Maunsbach K, McDonough AA. Effects of dietary salt on renal Na+ transporter subcellular distribution, abundance, and phosphorylation status. Am J Physiol Renal Physiol. 2008;295:F1003-F1016.
68. Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009;297:F1647-F1655.
69. Girardi AC, Degray BC, Nagy T, Biemesderfer D, Aronson PS. Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem. 2001;276:46671-46677.
70. Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol. 2011;301:F355-F363.
71. Girardi AC, Knauf F, Demuth HU, Aronson PS. Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol. 2004;287:C1238-C1245.
72. Rieg T, Gerasimova M, Murray F, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol. 2012;303:F963-F971.
73. Vallon V, Docherty NG. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4. Exp Physiol. 2014;99:1140-1145.
74. Lovshin JA, Rajasekeran H, Lytvyn Y, et al. Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1α1-67 in patients with type 2 diabetes. Diabetes Care. 2017;40:1073-1081.
75. Takashima S, Fujita H, Fujishima H, et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int. 2016;90:783-796.
76. Thomas MC. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab. 2017;43(suppl 1):2S20-2S27.
77. Poudyal H. Mechanisms for the cardiovascular effects of glucagon-like peptide-1. Acta Physiol (Oxf). 2016;216:277-313.
78. De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64:16-24.
79. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473-1478.
80. Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016;12:393-405.
81. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215-225.
82. Kawasoe S, Maruguchi Y, Kajiya S, et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017;18(1):23. https://doi.org/10.1186/s40360-017-0125-x.
83. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962-971.
84. Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9:e100777.
85. Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304:F156-F167.
86. Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302:R75-R83.
87. Gembardt F, Bartaun C, Jarzebska N, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol. 2014;307:F317-F325.
88. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772.
89. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
90. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. https://doi.org/10.1056/NEJMoa1611925.
91. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37:1526-1534.
92. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59:1860-1870.
93. Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014;16:875-882.
94. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibi-tion and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333-1339.
95. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16:467-477.
96. Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab. 2016;42:224-233.
97. Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012;32:80-94.
98. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10:2569-2576.
99. van Brummelen P, Man in 't Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther. 1980;27:328-336.
100. van Brummelen P, Schalekamp MA. Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. Acta Med Scand. 1980;207:259-264.
101. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993;153:973-980.
102. Zanella MT, Freire MB, Milagres R, et al. Blood pressure disturbance in diabetes mellitus. J Hypertens. 1992;10(suppl):S59-S70.
103. Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 2006;69:852-855.
104. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104-112.
105. Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol. 2014;25:2028-2039.
106. Coady MJ, El Tarazi A, Santer R, et al. MAP17 is a necessary activator of renal Na+/glucose cotransporter SGLT2. J Am Soc Nephrol. 2017;28:85-93.
107. Fu Y, Gerasimova M, Mayoux E, et al. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes. 2014;63(suppl 1):A132.
108. Baartscheer A, Schumacher CA, Wüst RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60:568-573.
109. Uthman L, Baartscheer A, Schumacher CA, et al. SGLT2 inhibitors inhibit NHE-1, lower [Na+]c and induced vasodilation, but only empaglilozin increases oxygen and glucose consumption in isolated mouse hearts. Presented at the American Diabetes Association Meeting; June 13, 2017; San Diego.
110. Joubert M, Jagu B, Montaigne D, et al. The SGLT2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 2017;66(4):1030-1040. https://doi.org/10.2337/db16-0733.
111. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15:157.
112. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025-1029. https://doi.org/10.1001/jamacardio.2017.2275.
113. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97.
114. Padda RS, Shi Y, Lo CS, Zhang SL, Chan JS. Angiotensin-(1-7): a novel peptide to treat hypertension and nephropathy in diabetes? J Diabetes Metab. 2015;6. https://doi.org/10.4172/2155-6156.1000615.
115. Shi Y, Lo CS, Padda R, et al. Angiotensin-(1-7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice. Clin Sci (Lond). 2015;128:649-663.
116. Zhang K, Meng X, Li D, et al. Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade. Kidney Int. 2015;87:359-369.
117. Oudit GY, Liu GC, Zhong J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59:529-538.
118. Shao C, Yu L, Gao L. Activation of angiotensin type 2 receptors partially ameliorates streptozotocin-induced diabetes in male rats by islet protection. Endocrinology. 2014;155:793-804.
119. Peluso AA, Santos RA, Unger T, Steckelings UM. The angiotensin type 2 receptor and the kidney. Curr Opin Nephrol Hypertens. 2017;26:36-42.
120. Koulis C, Chow BS, McKelvey M, et al. AT2R agonist, compound 21, is renoprotective against type 1 diabetic nephropathy. Hypertension. 2015;65:1073-1081.
121. Huang W, Gallois Y, Bouby N, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A. 2001;98:13330-13334.
122. Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis. 2008;51:613-623.
123. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008;74(12):1610-1616. https://doi.org/10.1038/ki.2008.497.
124. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
125. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
126. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
127. Shen J, Huang YM, Song XN, et al. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. J Renin Angiotensin Aldosterone Syst. 2016;17(3):pii: 1470320316656481.
128. Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, et al. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med. 2016;13(3):e1001971.
129. Banday AA, Lokhandwala MF. Angiotensin II-mediated biphasic regulation of proximal tubular Na+/H+ exchanger 3 is impaired during oxidative stress. Am J Physiol Renal Physiol. 2011;301:F364-F370.
130. He P, Klein J, Yun CC. Activation of Na+/H+ exchanger NHE3 by angiotensin II is mediated by inositol 1,4,5-triphosphate (IP3) receptor-binding protein released with IP3 (IRBIT) and Ca2+/calmodulin-dependent protein kinase II. J Biol Chem. 2010;285:27869-27878.
131. Xu L, Dixit MP, Nullmeyer KD, et al. Regulation of Na+/H+ exchanger-NHE3 by angiotensin-II in OKP cells. Biochim Biophys Acta. 2006;1758:519-526.
132. Eguti DM, Thieme K, Leung GP, Mello-Aires M, Oliveira-Souza M. Regulation of Na+/H+ exchanger isoform 1 (NHE1) by calmodulin-binding sites: role of angiotensin II. Cell Physiol Biochem. 2010;26:541-552.
133. Li XC, Shull GE, Miguel-Qin E, Chen F, Zhuo JL. Role of the Na+/H+ exchanger 3 in angiotensin II-induced hypertension in NHE3-deficient mice with transgenic rescue of NHE3 in small intestines. Physiol Rep. 2015;3(11):pii: e12605.
134. Nguyen MT, Han J, Ralph DL, Veiras LC, McDonough AA. Short-term nonpressor angiotensin II infusion stimulates sodium transporters in proximal tubule and distal nephron. Physiol Rep. 2015;3(9):pii: e12496.
135. McDonough AA. Mechanisms of proximal tubule sodium transport regulation that link extracellular fluid volume and blood pressure. Am J Physiol Regul Integr Comp Physiol. 2010;298:R851-RR61.
136. Lütken SC, Kim SW, Jonassen T, et al. Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade. Am J Physiol Renal Physiol. 2009;297:F1678-F1688.
137. Dixit MP, Xu L, Xu H, Bai L, Collins JF, Ghishan FK. Effect of angiotensin-II on renal Na+/H+ exchanger-NHE3 and NHE2. Biochim Biophys Acta. 2004;1664:38-44.
138. Stevens VA, Saad S, Poronnik P, Fenton-Lee CA, Polhill TS, Pollock CA. The role of SGK-1 in angiotensin II-mediated sodium reabsorption in human proximal tubular cells. Nephrol Dial Transplant. 2008;23:1834-1843.
139. Pontes RB, Girardi AC, Nishi EE, Campos RR, Bergamaschi CT. Crosstalk between the renal sympathetic nerve and intrarenal angiotensin II modulates proximal tubular sodium reabsorption. Exp Physiol. 2015;100:502-506.
140. Banday AA, Siddiqui AH, Menezes MM, Hussain T. Insulin treatment enhances AT1 receptor function in OK cells. Am J Physiol Renal Physiol. 2005;288:F1213-F1219.
141. 3 activity by angiotensin II is mediated by the activation of the angiotensin II type I receptor/phospholipase C/calcium/cal-modulin pathway in distal nephron cells. Eur J Pharmacol. 2013;721:322-331.
142. Castelo-Branco RC, Leite-Delova DC, de Mello-Aires M. Dose-dependent effects of angiotensin-(1-7) on the NHE3 exchanger and [Ca(2+)](i) in in vivo proximal tubules. Am J Physiol Renal Physiol. 2013;304:F1258-F1265.
143. Fan X, Liu K, Cui W, Huang J, Wang W, Gao Y. Novel mechanism of intra-renal angiotensin II-induced sodium/proton exchanger 3 expression by losartan in spontaneously hypertensive rats. Mol Med Rep. 2014;10:2483-2488.
144. Yang LE, Leong PK, McDonough AA. Reducing blood pressure in SHR with enalapril provokes redistribution of NHE3, NaPi2, and NCC and decreases NaPi2 and ACE abundance. Am J Physiol Renal Physiol. 2007;293:F1197-F1208.
145. Leong PK, Devillez A, Sandberg MB, et al. Effects of ACE inhibition on proximal tubule sodium transport. Am J Physiol Renal Physiol. 2006;290:F854-F863.
146. Sasson AN, Cherney DZ. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes. 2012;3:1-6.
147. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
148. Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure With reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial. Circ Heart Fail. 2016;9(1):pii:e002560.
149. Packer M, McMurray JJV. Importance of endogenous compensatory vaso-active peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet. 2017;389:1831-1840.
150. Zietse R, Derkx FH, Weimar W, Schalekamp MA. Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. J Am Soc Nephrol. 1995;5:2057-2066.
151. Ballermann BJ, Brenner BM. Atrial natriuretic peptide and the kidney. Am J Kidney Dis. 1987;10(suppl 1):7-12.
152. Zhang PL, Mackenzie HS, Troy JL, Brenner BM. Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats. J Am Soc Nephrol. 1994;4:1564-1570.
153. Jacobs EM, Vervoort G, Branten AJ, Klasen I, Smits P, Wetzels JF. Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption. Eur J Clin Invest. 1999;29:109-115.
154. Vervoort G, Wetzels JF, Lutterman JA, Bravenboer B, Berden JH, Smits P. Atrial natriuretic peptide-induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients. Am J Kidney Dis. 2002;40:9-15.
155. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920-926.
156. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615-620.
157. Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17:510-517.
158. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol. 1998;274:F63-F72.
159. Eiskjaer H, Nielsen CB, Sørensen SS, Pedersen EB. Renal and hormonal actions of atrial natriuretic peptide during angiotensin II or noradrenaline infusion in man. Eur J Clin Invest. 1996;26:584-595.
160. La Villa G, Fronzaroli C, Lazzeri C, et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J Clin Endocrinol Metab. 1994;78:1166-1171.
161. Eiskjaer H, Pedersen EB. Dose-response study of atrial natriuretic peptide bolus injection in healthy man. Eur J Clin Invest. 1993;23:37-45.
162. García-Estañ J, Roman RJ. Role of renal interstitial hydrostatic pressure in natriuretic response to ANP. Am J Physiol. 1990;258:R1333-R1339.
163. Solomon LR, Atherton JC, Bobinski H, Hillier V, Green R. Effect of low dose infusion of atrial natriuretic peptide on renal function in man. Clin Sci (Lond). 1988;75:403-410.
164. Biollaz J, Bidiville J, Diézi J, et al. Site of the action of a synthetic atrial natriuretic peptide evaluated in humans. Kidney Int. 1987;32:537-546.
165. Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature. 1987;326:697-698.
166. Thomson SC, Deng A. Cyclic GMP mediates influence of macula densa nitric oxide over tubuloglomerular feedback. Kidney Blood Press Res. 2003;26:10-18.
167. Piquard F, Richard R, Charloux A, et al. Hormonal, renal, hemodynamic responses to acute neutral endopeptidase inhibition in heart transplant patients. J Appl Physiol (1985). 2002;93:569-575.
168. Jandeleit-Dahm K, Lassila M, Davis BJ, et al. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibi-tion in diabetic apolipoprotein E-knockout mice. J Hypertens. 2005;23:2071-2082.
169. Davis BJ, Johnston CI, Burrell LM, et al. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia. 2003;46:961-971.
170. Roksnoer LC, van Veghel R, van Groningen MC, et al. Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone. Clin Sci (Lond). 2016;130:1209-1220.
171. Taal MW, Nenov VD, Wong W, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol. 2001;12:2051-2059.
172. Regamey F, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal hemodynamic and natriuretic effects of concomitant angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension. 2002;40:266-272.
173. Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69:32-41.
174. Lazzeri C, Franchi F, Porciani C, et al. Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension. Am J Hypertens. 1995;8:799-807.
175. Amorena C, Castro AF. Control of proximal tubule acidification by the endothelium of the peritubular capillaries. Am J Physiol. 1997;272:R691-R694.
176. Cha B, Kim JH, Hut H, et al. cGMP inhibition of Na+/H+ antiporter 3 (NHE3) requires PDZ domain adapter NHERF2, a broad specificity protein kinase G-anchoring protein. J Biol Chem. 2005;280:16642-16650.
177. Jin XH, Siragy HM, Carey RM. Renal interstitial cGMP mediates natriuresis by direct tubule mechanism. Hypertension. 2001;38:309-316.
178. Graebe M, Brond L, Christensen S, Nielsen S, Olsen NV, Jonassen TE. Chronic nitric oxide synthase inhibition exacerbates renal dysfunction in cirrhotic rats. Am J Physiol Renal Physiol. 2004;286:F288-F297.
179. Oxlund CS, Buhl KB, Jacobsen IA, et al. Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension. J Am Soc Hypertens. 2014;8:872-881.
180. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007;9(suppl 1):19-24.
181. Andersen H, Hansen PB, Bistrup C, Nielsen F, Henriksen JE, Jensen BL. Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy. J Hypertens. 2016;34:1621-1629.
182. Edelman IS, Fimognari GM. On the biochemical mechanism of action of aldosterone. Recent Prog Horm Res. 1968;24:1-44.
183. El Mernissi G, Doucet A. Short-term effects of aldosterone and dexamethasone on Na-K-ATPase along the rabbit nephron. Pflugers Arch. 1983;399:147-151.
184. Frindt G, Palmer LG. K+ secretion in the rat kidney: Na+ channel-dependent and -independent mechanisms. Am J Physiol Renal Physiol. 2009;297:F389-F396.
185. De Smet P, Simaels J, Van Driessche W. Regulatory volume decrease in a renal distal tubular cell line (A6). I. Role of K+ and Cl-aaaaaaaa. Pflugers Arch. 1995;430:936-944.
186. Hofni A, El-Moselhy MA, Taye A, Khalifa MM. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. Eur J Pharmacol. 2014;744:173-182.
187. Mavrakanas TA, Cheva A, Kallaras K, Karkavelas G, Mironidou-Tzouveleki M. Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats. Pharmacology. 2010;86:85-91.
188. Lian M, Hewitson TD, Wigg B, Samuel CS, Chow F, Becker GJ. Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrol Dial Transplant. 2012;27:906-912.
189. Yuan J, Jia R, Bao Y. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst. 2007;8:118-126.
190. Taira M, Toba H, Murakami M, et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol. 2008;589:264-271.
191. Kang YS, Ko GJ, Lee MH, et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant. 2009;24:73-84.
192. Nishikawa T, Suematsu S, Saito J, et al. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol. 2005;96:309-316.
193. Mavrakanas TA, Gariani K, Martin PY. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Eur J Intern Med. 2014;25:173-116.
194. Ustundag A, Tugrul A, Ustundag S, Sut N, Demirkan B. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren Fail. 2008;30:982-991.
195. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536-542.
196. Pinto V, Pinho MJ, Hopfer U, Jose PA, Soares-da-Silva P. Oxidative stress and the genomic regulation of aldosterone-stimulated NHE1 activity in SHR renal proximal tubular cells. Mol Cell Biochem. 2008;310:191-201.
197. Zhang M, Chen J, Liu S, You L, Lin S, Gu Y. The role of Na+-H+ exchanger isoform 1 in aldosterone-induced glomerulosclerosis in vivo. Ren Fail. 2009;31:726-735.
198. Drumm K, Kress TR, Gassner B, Krug AW, Gekle M. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell Physiol Biochem. 2006;17:21-28.
199. Zhang M, Chen J, Lai L, et al. Aldosterone promotes fibronectin synthesis in rat mesangial cells via ERK1/2-stimulated Na-H+ exchanger isoform 1. Am J Nephrol. 2010;31:75-82.
200. Krug AW, Papavassiliou F, Hopfer U, Ullrich KJ, Gekle M. Aldosterone stimulates surface expression of NHE3 in renal proximal brush borders. Pflugers Arch. 2003;446:492-496.
201. Ambühl P, Amemiya M, Preisig PA, Moe OW, Alpern RJ. Chronic hyperosmolality increases NHE3 activity in OKP cells. J Clin Invest. 1998;101:170-177.
202. Li Z, Zhang L, Shi W, et al. Spironolactone inhibits podocyte motility via decreasing integrin β1 and increasing integrin β3 in podocytes under high-glucose conditions. Mol Med Rep. 2015;12:6849-6854.
203. Toyonaga J, Tsuruya K, Ikeda H, et al. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant. 2011;26:2475-2484.
204. Nishiyama A, Kobori H, Konishi Y, et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther. 2010;332:1072-1080.
205. Lee SH, Yoo TH, Nam BY, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol. 2009;297:F1381-F1390.
206. + exchanger type 1 and intracellular pH in angiotensin II-induced reactive oxygen species generation and podocyte apoptosis. J Pharmacol Sci. 2013;122:176-183.
207. Kellenberger S, Gautschi I, Schild L. Mutations in the epithelial Na+ channel ENaC outer pore disrupt amiloride block by increasing its dissociation rate. Mol Pharmacol. 2003;64:848-856.
208. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
209. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
210. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919-928.
211. Geng Q, Ren J, Song J, Li S, Chen H. Meta-analysis of the effect of statins on renal function. Am J Cardiol. 2014;114:562-570.
212. Nikolic D, Banach M, Nikfar S, et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol. 2013;168:5437-5447.
213. Lin CL, Cheng H, Tung CW, et al. Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt signaling pathway. Am J Nephrol. 2008;28:290-297.
214. Zhu B, Shen H, Zhou J, Lin F, Hu Y. Effects of simvastatin on oxidative stress in streptozotocin-induced diabetic rats: a role for glomeruli protection. Nephron Exp Nephrol. 2005;101:e1-e8.
215. Blanco S, Vaquero M, Gómez-Guerrero C, López D, Egido J, Romero R. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens. 2005;18(4, pt 1):557-565.
216. Qin J, Zhang Z, Liu J, et al. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int. 2003;64:565-571.
217. Zoja C, Corna D, Gagliardini E, et al. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol. 2010;299:F1203-F1211.
218. Zhou S, Zhao P, Li Y, Deng T, Tian L, Li H. Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism. Eur J Pharmacol. 2014;740:9-14.
219. Singh RS, Chaudhary DK, Mohan A, et al. Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone de-acetylase inhibitor. Sci Rep. 2016;6:38034. https://doi.org/10.1038/srep38034.
220. Giunti S, Calkin AC, Forbes JM, et al. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am J Physiol Renal Physiol. 2010;299:F528-F535.
221. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
222. Hermans MP. Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diab Vasc Dis Res. 2011;8:180-189.
223. Bonds DE, Craven TE, Buse J, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. 2012;55:1641-1650.
224. Ruggenenti P, Cattaneo D, Rota S, et al. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care. 2010;33:1954-1956.
225. Ng LL, Davies JE. Lipids and cellular Na+/H+ antiport activity in diabetic nephropathy. Kidney Int. 1992;41:872-876.
226. Ng LL, Davies JE. HMG CoA reductase inhibitors affect Na(+)-H+ antiport activity in human lymphoblasts. Am J Physiol. 1991;261:C780-C786.
227. Davies JE, Ng LL. Simvastatin and intracellular pH regulation by the Na+/H+ antiport of SV40-virus-transformed human MRC5 fibroblasts. Clin Sci (Lond). 1993;84:633-643.
228. Johnson DW, Saunders HJ, Field MJ, Pollock CA. In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity. Am J Physiol. 1999;276:F467-F475.
229. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998;31:225-231.
230. Juncos LI, Martín FL, Baigorria ST, et al. Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency. Nutrition. 2012;28:e23-e28.
231. Paulsen L, Matthesen SK, Bech JN, Starklint J, Pedersen EB. Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes. J Clin Pharmacol. 2010;50:816-822.
232. Paulsen L, Holm C, Bech JN, Starklint J, Pedersen EB. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans. Nephrol Dial Transplant. 2008;23:1556-1561.
233. Briasoulis A, Agarwal V, Valachis A, Messerli FH. Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J Clin Hypertens (Greenwich). 2013;15:310-320.
234. Boyce SW, Bartels C, Bolli R, et al. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarc-tion in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg. 2003;126:420-427.
235. Chang HB, Gao X, Nepomuceno R, Hu S, Sun D. Na(+)/H(+) exchanger in the regulation of platelet activation and paradoxical effects of cariporide. Exp Neurol. 2015;272:11-16.
236. Schultheis PJ, Clarke LL, Meneton P, et al. Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat Genet. 1998;19:282-285.
237. Chan LKY, Wang Y, Ng EKW, Leung PS. NHE3 blockade ameliorates type 2 diabetes mellitus via inhibition of SGLT1-mediated glucose absorption in the small intestine. Diabetes Obes Metab. 2018;20:709-717.
238. Linz D, Wirth K, Linz W, et al. Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut. Hypertension. 2012;60:1560-1567.
239. + exchanger NHE3: effects on bicarbonate absorption and ammonium excretion. J Mol Med (Berl). 2013;91:951-963.
240. Fenton RA, Poulsen SB, de la Mora Chavez S, et al. Caffeine-induced diuresis and natriuresis is independent of renal tubular NHE3. Am J Physiol Renal Physiol. 2015;308:F1409-F1420.
241. Watanabe S, Ogasawara T, Tamura Y, et al. Targeting gene expression to specific cells of kidney tubules in vivo, using adenoviral promoter fragments. PLoS One. 2017;12(3):e0168638. https://doi.org/10.1371/journal.pone.0168638.
242. Chen T, Kocinsky HS, Cha B, et al. Cyclic GMP kinase II (cGKII) inhibits NHE3 by altering its trafficking and phosphorylating NHE3 at three required sites: identification of a multifunctional phosphorylation site. J Biol Chem. 2015;290:1952-1965.
243. Sarker R, Cha B, Kovbasnjuk O, et al. Phosphorylation of NHE3-S719 regulates NHE3 activity through the formation of multiple signaling complexes. Mol Biol Cell. 2017;28:1754-1767.
244. He P, Zhao L, No YR, Karvar S, Yun CC. The NHERF1 PDZ1 domain and IRBIT interact and mediate the activation of Na+/H+ exchanger 3 by ANG II. Am J Physiol Renal Physiol. 2016;311:F343-F351.
245. Babich V, Di Sole F. The Na+/H+ exchanger-3 (NHE3) activity requires ezrin binding to phosphoinositide and its phosphorylation. PLoS One. 2015;10:e0129306.
246. Singh V, Yang J, Cha B, et al. Sorting nexin 27 regulates basal and stimulated brush border trafficking of NHE3. Mol Biol Cell. 2015;26:2030-2043.